Vermont plans Rx bidding for Medicaid

13 February 2001

In the USA, the Vermont House of Representatives' Health and WelfareCommittee is working on a bill that could save up to 40% on the cost of prescription drugs that the state provides for its Medicaid beneficiaries.

The plan calls for pharmaceutical companies to bid competitively to supply drugs on the state formulary, reports the Associated Press. Consumers could use the drug on the formulary or another one, and doctors could indicate if another treatment is preferred for a patient.

Other provisions included in the bill are: - incentives to establish more federally-qualified health centers, whose patients would be entitled to the federal government's best prices on prescriptions; - an initiative to teach doctors and consumers about the prices of particular drugs and lower-cost alternatives; and - setting up a catastrophic fund which would be available after consumers had spent a set percentage of their income, which would vary according to income relative to the government's poverty line.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight